BD BIOSCIENCES FACS CANTO FLOW CYTOMETER: CANCER: MELANOMA, GLIOMA

该子项目是利用由NIH/NCRR资助的共享仪器补助金提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是资助机构，不一定是研究者的机构。描述（由申请人提供）：本申请要求为阿拉巴马大学伯明翰分校细胞和组织工程实验室（LCTE）购买BD Biosciences FACS Canto流式细胞仪。该仪器将用于取代已有12年历史的BD Biosciences FACS Sort细胞仪，该仪器需要频繁维修，有时会影响实验室的功能。该仪器将允许实验室在未来继续为用户服务，并扩展功能以允许六色流式细胞术。LCTE是一个符合CLIA、CAP和fact标准的核心设施，由综合癌症中心、艾滋病研究中心和镰状细胞中心提供支持。LCTE为UAB研究人员提供了一个翻译有前途的细胞治疗（包括基因修饰细胞治疗）方案的平台。该设施提供从临床前开发的最早阶段到临床级材料的制备和ind的提交的支持。在LCTE中产生的许多细胞产品都是在洁净室环境中制备的。当前的流式细胞仪位于相邻的实验室，可以直通到洁净套房，可以立即进行现场分析，并与准备移植物的团队进行咨询。由于移植物工程工作通常需要多个步骤，在处理过程中的关键决策之前需要流式细胞术分析，因此将标本运送到另一个设备进行分析将不必要地延长处理时间，并可能损害产品。此外，当LCTE细胞仪不用于细胞移植评估时，它可用于综合癌症中心，艾滋病研究中心和美国国立卫生研究院资助的脑肿瘤孢子研究人员的溢出工作，这些研究人员需要在clia批准的实验室中使用51 OK批准的仪器。首席研究员最近得到了阿拉巴马大学卫生服务基金会的资助，进行了LCTE的重大扩展，包括体细胞治疗、心肌再生、镰状细胞病的基因治疗、自身免疫性疾病的树突状细胞和调节细胞治疗以及骨再生的方案。这些方案，加上现有的造血细胞治疗和免疫治疗试验即将获得批准，将在未来两年内大幅增加用户数量。该实验室将需要一个仪器，将服务于实验室的发展和执行先进的细胞治疗试验。

This subproject is one of many research subprojects utilizing the resources provided by a Shared Instrumentation Grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the grant, which is not necessarily the institution for the investigator. DESCRIPTION (provided by applicant): This application requests funds to purchase the BD Biosciences FACS Canto flow cytometer for the Laboratory for Cellular and Tissue Engineering (LCTE) at the University of Alabama at Birmingham. The instrument will be used to replace a 12 year old BD Biosciences FACS Sort cytometer that has required frequent servicing that at times has impacted the functioning of the laboratory. This instrumentation will allow the laboratory to continue to serve its users well into the future and to expand functionality to allow six-color flow cytometry. The LCTE is a CLIA, CAP, and FACT-compliant core facility supported by the Comprehensive Cancer Center, the Center for AIDS Research, and the Sickle Cell Center. The LCTE provides a platform for translation of promising cellular therapy (including gene-modified cellular therapy) protocols for UAB investigators. The facility provides support from the earliest level of preclinical development to the preparation of clinical grade materials and submission of INDs. Many cell products that are generated in the LCTE are prepared in a clean room environment. The current flow cytometer is located in an adjacent laboratory with a pass-through to the clean suites allowing immediate on-site analysis and consultation with the team that is preparing the graft. Since the graft engineering work often requires multiple steps with flow cytometric analysis required prior to critical decisions during processing, transport of the specimens to another facility for analysis would unnecessarily prolong the processing and potentially compromise the product. In addition, when the LCTE cytometer is not being used for cellular graft evaluation, it is available for overflow work from the Comprehensive Cancer Center, Center for AIDS Research, and the Brain Tumor SPORE NIH-funded investigators that require a 51 OK approved instrument in a CLIA-approved laboratory for their protocols. The Principal Investigator has recently been funded by the University of Alabama Health Services Foundation to undertake a major expansion of the LCTE to include protocols for somatic cell therapy, myocardial regeneration, gene therapy for sickle cell disease, dendritic cell and regulatory cell therapy for autoimmune disorders, and bone regeneration. These protocols, in addition to existing hematopoietic cell therapy and immunotherapy trials nearing approval, will substantially increase the number of users over the next two years. The laboratory will require an instrument that will serve the laboratory in the development and execution of advanced cell therapy trials.